REGN241025P1000000
- 34.57
- +13.95+67.65%
Regeneron Pharmaceuticals Newsroom
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $1,205 From $1,245
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,137
Regeneron Pharma Is Maintained at Buy by Truist Securities
Regeneron Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,235
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Regeneron Pharmaceuticals Analyst Ratings
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating
Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,247
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,245
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target